Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.mannin.ca
Number of Employees: -
Year Founded: -
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Mannin Research Inc., a biotechnology company, develops vascular therapeutics using a research platform. It develops drugs for the treatment of diseases, such as glaucoma and cystic kidney disease. The company offers therapeutic eye-drops for the treatment of glaucoma in adults and children. Mannin Research Inc. is based in Toronto, Canada. As per the transaction announced on September 21, 2015, Mannin Research Inc. operates as a subsidiary of Q BioMed Inc.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Nikopoulos, George N.
Chief Executive Officer and President
Quaggin, Susan E.
Chief Scientific Officer and Director
Smith, Geoffrey D.
Secretary and Director

Key Board Members
Name
Title
Smith, Christopher A.
Chairman
Smith, Geoffrey D.
Secretary and Director


Primary Industry Classification
Biotechnology


Primary Office Location
75 International Boulevard Suite 300 | Toronto, ON | M9W 6L9 | Canada
Phone: 416-306-2853   

Parent Company
Q BioMed Inc. (OTCPK:QBIO)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-21-2015
-
Merger/Acquisition
Target
Mannin Research Inc.
Q BioMed Inc. (OTCPK:QBIO)

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jul-14-2022
Company Conference Presentations
Mannin Research Inc. Presents at 2nd Annual ARDS Drug Development Summit, Jul-14-2022 09:40 AM
Aug-26-2020
Product-Related Announcements
Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program
Apr-22-2020
Strategic Alliances
Q BioMed Inc. and Mannin Research Initiates Rapid Development of Novel Covid-19 Therapeutics
Feb-07-2020
Company Conference Presentations
Mannin Research Inc. Presents at 9th Annual Glaucoma 360 New Horizons Forum, Feb-07-2020 02:25 PM
Feb-04-2020
Strategic Alliances
Q BioMed Partner Mannin Research Develops Potential Treatment for Patients Infected with Coronavirus and Other Infectious Diseases


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 18, 2023 03:44 AM
Mannin Research Inc.
Mannin Research Inc
Reports
27
GlobalData

Jun 15, 2023 11:25 PM
Mannin Research Inc.
Mannin Research Inc
Reports
27
GlobalData

Mar 14, 2023 02:31 AM
Mannin Research Inc.
Mannin Research Inc
Reports
28
GlobalData

Dec 15, 2022 01:50 AM
Mannin Research Inc.
Mannin Research Inc
Reports
28
GlobalData

Sep 21, 2022 07:48 AM
Mannin Research Inc.
Mannin Research Inc
Reports
34
GlobalData

Jun 14, 2022 02:58 AM
Mannin Research Inc.
Mannin Research Inc
Reports
34
GlobalData

Mar 14, 2022 07:50 AM
Mannin Research Inc.
Mannin Research Inc
Reports
33
GlobalData

Dec 16, 2021 03:30 AM
Mannin Research Inc.
Mannin Research Inc
Reports
36
GlobalData

Sep 16, 2021 09:55 AM
Mannin Research Inc.
Mannin Research Inc
Reports
26
GlobalData

Jun 19, 2021 09:45 PM
Mannin Research Inc.
Mannin Research Inc
Reports
26


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Smith, Christopher A.
Chairman
416-306-2853
-
-
Smith, Geoffrey D.
Secretary and Director
416-306-2853
-
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Nikopoulos, George N.
Chief Executive Officer and President
416-306-2853
-
-
Quaggin, Susan E.
Chief Scientific Officer and Director
416-306-2853
-

Smith, Geoffrey D.
Secretary and Director
416-306-2853
-
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
